Our mission is to introduce innovative, high-quality intrauterine drug-delivery
technology to improve and impact women’s health and quality of life.
OCON Healthcare innovates, develops, manufactures, and commercializes cutting-edge women’s health products based on our patented IUB™ (Intra Uterine Ball) proprietary platform. The IUB™, made from a super-elastic alloy Nitinol, is an ideal carrier for multiple drugs to the uterus to treat a variety of conditions.
Chief Executive Officer
Keren Leshem, OCON’s CEO, is a seasoned executive with over 20 years’ experience in the medical device & pharmaceutical industries specializing in the management of innovative start-ups, strategy, commercialization, BD and financing. Ms. Leshem holds an MBA from Clark University.
VP Marketing & Medical Affairs
Daniela Schardinger, OCON’s VP Marketing & Medical affairs, has well over a decade of experience in Marketing, Sales and Medical Management in the medical device and pharmaceutical industries around the globe. Ms. Schardinger holds a MSc in Information Design and Marketing.
Chief Technology Officer
Shani Eliyahu-Gross, OCON’s CTO, has more than a decade of a demonstrated success in implantable products and medical devices. Dr. Eliyahu-Gross holds a M.Sc. from the Weizmann Institute and a Ph.D. in Chemistry from Ben-Gurion University, Israel. In her department she oversees the R&D activities and the Regulatory/QA activities in both commercial assets as well as products in development stage.
VP Clinical Affairs
Dana Raveh-Arbel, OCON’s VP Clinical Affairs, brings over 15 years of experience in clinical research and clinical trial management in the BioMedical industry.
Susanne Mair, OCON’s European Operations, brings more than 4 years of experience as a European Sales and Marketing Manager in the medical device field. Prior to joining OCON Healthcare in May 2020, Dr. Mair identified, selected and built up several markets in Europe for an Israeli startup, IOPtima Ltd, with focus on ophthalmology, and rebranded and launched a new product.
Country Manager Israel
Avital Gilad, OCON Israel’s Country Manager, is an experienced Brand Manager with a demonstrated history of working in the pharmaceuticals industry. Skilled in Marketing Management, Pharmaceutics, Business Planning, Oncology, and Key Opinion Leaders. Ms. Gilad is a strong marketing professional with a Bachelor’s degree focused in Comunication disorders from Tel Aviv University.
Chief Financial Officer
Amir Avraham, OCON’s CFO, hails from Secure Islands, a company acquired by Microsoft, and prior to that was CFO of Van Leer Ventures Jerusalem. A certified accountant, Mr. Avraham has a BA in Accounting & Economics and a MBA.
Eran Nir, OCON’s VP R&D, is responsible for R&D and technology aspects, relying on his extensive development and pre-clinical expertise in companies such as J&J and Chiasma Pharma. Dr. Nir holds a PhD in Biology from Tel Aviv University.
Dr Medy Wiener is a multidisciplinary high-level executive that brings more than two decades of experience in the global Pharma and Biotech field with a diverse skill and
a proven track record in drug development, pharmacovigilance, medical affairs, business development and strategy.
She served in various management positions in global Pharma companies – Chief Medical Officer at BOL Pharma, Chief Scientific Officer in Novartis Pharma, VP Corporate Strategy at Teva and lately as Head of BD and Medical Affairs at Allergan. Dr Wiener holds a Medical Doctor degree from Tel Aviv university and an MBA from the Interdisciplinary Center and was trained at Cardiff University in Pharmaceutical Medicine.
Meir Rimer, OCON’s Operations Manager, has well over ten years of experience in biomedical companies such as Macrocure and Glycominds. Mr. Rimer holds a BSC in Chemistry of Materials and an MBA.
Director of Regulatory Affairs
Niva Peleg, OCON’s Director of Quality & Regulatory Affairs, is a QA/RA professional with 7 years of experience in handling quality systems and regulatory activities in medical & pharmaceutical companies.
Board of Directors
Anula Jayasuriya, MD, PhD, MBA, Chairwoman
Founder & Managing Director, EXXclaim Capital; Co-founder Evolvence India Life Science Fund. Anula Jayasuriya is a successful private equity executive and venture capitalist whose background combines deep business, scientific and medical knowledge with broad clinical, industry, entrepreneurial, and investment experience. She serves on the boards of several biotechnology companies, and also serves non-profit boards. Ms. Jayasuriya holds a BA (summa cum laude) from Harvard, an MD and PhD from Harvard Medical School as well as an MBA with distinction from Harvard Business School and an M. Phil. in pharmacology from the University of Cambridge, in England.
Keren Leshem, MBA
Keren Leshem, OCON’s CEO, is a seasoned executive with over 20 years’ experience in the medical device & pharmaceutical industries specializing in the management of innovative start-ups, strategy, commercialization, BD, and financing. Ms. Leshem holds an MBA from Clark University.
Tomer Kariv, LLB
Co-founder and Chief Executive Officer of Pontifax. Tomer serves as a board member at Eloxx Pharmaceuticals, LogicBio Therapeutics, VBI Vaccines, Cathworks and V-Wave among others and holds a B.A. in Economics from Harvard University and a J.D. from Harvard Law School.
Asaf Shinar, CPA
Mr. Shinar is the CFO of The Pontifax Group. The fund runs more than 50 portfolio companies all around the globe.
Adi Goldin, LLB
Mr. Goldin is Docor’s Vice President and has over 15 years of experience in the life science, industrial and hi-tech industries in the areas of investments, business strategy, deal structure and company management. Mr. Goldin holds a Masters in Economics as well as a LLB.
Stasia Obremskey, MBA
Stasia Obremsky, Managing Director of Rhia Ventures, has more than twenty-five years of experience providing financial and strategic planning consulting to organizations in the U.S. and Asia. She joins management teams as an interim Chief Financial Officer to provide finance, accounting and strategic planning expertise to startups, fast growing companies and nonprofit organizations. As a philanthropist, she holds leadership positions with Upstream USA, the Gladstone Institute, Room to Read, and the Chinese American International School.
Robert Auerbach, MD
Dr. Auerbach has over 20 years of experience in medical and business leadership positions in the women’s healthcare industry, and over 36 years of experience in OB/GYN with the Yale OB/GYN/RS department. He most recently served as President of CooperSurgical Worldwide, the CooperCompanies women’s healthcare division, and before that as EVP, Chief Medical Officer and Chief Strategy Officer of CooperSurgical. Prior to joining CooperSurgical, he served as an Associate Clinical Professor in the Department of Obstetrics, Gynecology & Reproductive Sciences at the Yale School of Medicine.
Barak Mevorak, MD
Dr. Barak Mevorak has over 25 years experience in the healthcare industry as an Investor, practitioner, consultant, and business owner.
Barak has taken part in implementing and executing software development projects for managed care organizations and other institutions such as hospitals and provider based institutions.
Barak completed his specialty training in Internal Medicine and a residency in Physical Medicine & Rehabilitation at UCLA.
Rani Lifshitz, LLB
Active Chairman of Merchavia Holdings ,a publicly traded company (TASE) , specializing in life science investments having a strategic partnership with the innovation arm of Cleveland Clinic – a leading medical Center in the USA. Rani has more than twenty -five years of senior positions in the global energy sector and medical investments . Rani founded an Energy company , with one of the biggest financial groups in Israel and led it to a successful exit . Rani holds LLB degree and BA in economics .